Frailty and Cirrhosis: Bridging the Gap to Transplantation

Frailty and Cirrhosis: Bridging the Gap to Transplantation

Lecture Summary — Andres Duarte, MD

1. Main Clinical Topics Discussed

• Assessment and prognostic significance of physical frailty and sarcopenia in patients with cirrhosis
• Integration of cardiorespiratory fitness (CRF) as a physiological reserve metric
• Impact of frailty on pre- and post-liver transplant outcomes
• Practical tools for frailty assessment and waitlist management
• Role of prehabilitation and patient-reported outcomes in transplant candidates

2. Key Learning Points, Guidelines, and Recommendations

Frailty vs. Sarcopenia — A Unified Spectrum:

• Sarcopenia (anatomic muscle loss) and frailty (functional decline) exist on a broader continuum of physical fitness / physiological reserve
• This spectrum extends from malnutrition → sarcopenia → frailty → impaired cardiorespiratory fitness

Assessment Tools Available:

• CT-based Skeletal Muscle Index (SMI) — anatomic sarcopenia standard
• Phase Angle (bioelectrical impedance) — comparable to CT for sarcopenia identification; not affected by ascites
• Liver Frailty Index (LFI) — combines handgrip strength, five-times chair stand, and three-position balance test; frailty threshold: LFI ≥ 4.5
• Six-Minute Walk Test (6MWT) — cardiorespiratory fitness proxy; frailty threshold: < 250 meters
• Cardiopulmonary Exercise Testing (CPX/CPET) — gold-standard CRF assessment; most sensitive, detects impairment even in pre-frail patients
• Step monitoring (wearables/fitbits) — community-based CRF surrogate; < 1,000 steps/day associated with highest risk

Key Recommendation:

• The American Heart Association endorses CRF as a clinical vital sign, arguing it predicts overall and cardiovascular mortality more accurately than traditional risk factors (diabetes, dyslipidemia, hypertension, smoking)
• Clinicians should choose tools best suited to their center and patient population; subjective questionnaires alone are insufficient

3. Specific Clinical Data, Statistics, and Study Results

Sarcopenia:

• Meta-analysis of 22 studies, ~7,000 cirrhosis patients: sarcopenia prevalence ranges from 28% (Child-Pugh A) to 47% (Child-Pugh C)
• Sarcopenia associated with approximately double the risk of mortality (hazard ratio ~2.0)
• Phase angle demonstrated equivalent prognostic accuracy to CT-defined sarcopenia and was unaffected by ascites

Liver Frailty Index (LFI):

• LFI predicts waitlist mortality with AUROC ~0.72, comparable to MELD-sodium; combined use improves accuracy
• LFI ≥ 5.0 → approximately 25% waitlist mortality
• Frail patients have approximately 91% increased mortality compared to non-frail patients with identical MELD-sodium scores
• Frailty increases mortality irrespective of decompensation type (ascites, hepatic encephalopathy, or both) — confirmed in multivariable competing-risk analysis

Six-Minute Walk Test:

• Patients walking < 250 meters have approximately triple the pre-transplant mortality, independent of age and MELD-sodium
• Each 50-meter decline in 6MWT distance → 10% decreased likelihood of reaching transplantation and 11% increased risk of hospital admission
• No statistically significant increase in post-transplant mortality based on 6MWT category

Post-Transplant Outcomes (LFI Consortium, ~1,200 patients):

• Frailty associated with significantly increased 1-year and 3-year post-transplant mortality
• No identifiable LFI threshold at which post-transplant survival fails to exceed pre-transplant survival — supporting transplantation even in frail patients
• Frailty consistently increases **